SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is drawing attention amid a selloff in AI infrastructure stocks and concerns that its heavy debt load and costly financing could constrain growth. Traders are split between warnings about dilution and default risk and bullish arguments about AI-compute demand, with Goldmans upgrade and ARKs purchases cited as counterpoints that have not settled the debate.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO selloff is dominating discussion, with traders citing successive share unlocks and insider selling, a TD Cowen price-target cut, and concerns about OpenAI customer concentration and the companys ability to scale. Sentiment is largely bearish, though some investors view the decline as oversold and are averaging down.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcoms sharp underperformance amid a semiconductor selloff has fueled debate over AI spending sustainability and financing risks, with traders also citing CEO Hock Tans casino remarks as a drag on sentiment. Some see the decline as a buying opportunity, while others fear the AI trade is losing momentum.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing attention over concerns that its debt-funded AI data-center expansion, heavy capital spending and weak free cash flow could strain its credit profile, amid broader doubts about AI infrastructure financing and demand. Many traders remain bearish after the selloff, while others argue Oracles cloud business and backlog can eventually generate returns; speculation about financing arrangements and an upcoming investor event also appears.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a steep AI-infrastructure selloff tied to concerns about neocloud financing, debt, and whether massive data-center spending will earn adequate returns, followed by a volatile rebound. Traders are split between viewing the decline as an oversold buying opportunityoften arguing NBIS is better positioned than CoreWeaveand expecting rallies to fade as sector and market uncertainty persists.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is drawing attention as the S&P 500 rebounds after a tech-led selloff, with investors watching upcoming major-company earnings for signs the recovery can hold. Traders are split between viewing the move as a relief bounce and expecting further downside, amid concerns about AI spending and debt, oil prices, and weak market breadth.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths third-quarter earnings beat and raised full-year outlook, supported by improved medical-cost control, are driving attention. Traders are split between viewing the results as evidence of a turnaround and questioning whether the margin improvement will last, while many reacted to the stocks volatile, initially muted response to the report.

Silicon Motion Technology Corp. engages in the development, manufacture, and supply of semiconductor products for the electronics market. The firm’s products include Flash Controllers, Storage Solutions, and others. It offers embedded and expandable storage, radio frequency integrated circuits, and embedded graphics. The company was founded by Wallace C. Kou in November 1995 and is headquartered in Hong Kong.

Silicon Motion Technology Corp - ADR

Silicon Motion Technology Corp.

SIMO is drawing attention for its growth in AI and data-center storage, particularly boot-drive shipments and MonTitan enterprise SSD controllers, alongside strong results and an upbeat outlook. Many traders see room for further growth, while others point to sharp share-price swings, technical weakness and dilution concerns tied to convertible notes.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led relief rally after a sharp AI-related selloff has put QQQ in focus, with traders debating whether the volatile rebound signals recovery or is a temporary bounce. Upcoming megacap earnings are a key test, while concerns about AI infrastructure spending and weak market breadth sustain bearish views.

Aventus Network

AVT is drawing attention as traders watch a volatile, thinly traded rebound for a breakout, focusing on trading volume and resistance levels. Aventus Clouds decentralized-compute and enterprise-appchain updates provide a bullish project narrative, but traders remain divided over whether momentum can persist amid low liquidity and selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Traders are focused on the administration weighing temporary permission for compounding pharmacies to sell certain restricted peptides, which could create a new opportunity for Hims & Hers but is not a finalized approval. The community sees potential upside from a peptide launch, while skeptics point to recurring failed rallies and continued range-bound trading.

Robbins LLP Reminds HIMS Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm Before November 2, 2026, for Information About Leading the Lawsuit Against Hims & Hers Health, Inc.

Robbins LLP Reminds HIMS Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm Before November 2, 2026, for Information About Leading the Lawsuit Against Hims & Hers Health, Inc. Robbins LLP Reminds HIMS Investors of the Pending Class Action Lawsuit; Harmed...

What Does Hims & Hers Health, Inc.'s 14.73% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline

What Does Hims & Hers Health, Inc.'s 14.73% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline What Does Hims & Hers Health, Inc.'s 14.73% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines...

HIMS Deadline: HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit

HIMS Deadline: HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit HIMS Deadline: HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Oct. 17, 2026 NEW YORK, Oct. 17, 2026 /PRNewswire/ -- Why: Rosen Law...

Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS

Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of...

Hims & Hers Health (HIMS) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline

Hims & Hers Health (HIMS) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline Hims & Hers Health (HIMS) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before...

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know  

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

HIMS Stock Snaps 3-Day Slump On Peptide Hopes: Trump Administration Reviews Plan That Could Unlock $2.2B Market 

Equity

The plan would apparently temporarily allow specialty pharmacies to compound certain unapproved peptides, including BPC-157.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action...

HIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - November 2, 2026 Deadline

HIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - November 2, 2026 Deadline HIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - November 2, 2026...

Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.72, denoting a -6.7% move from the preceding trading day.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Bearish Sentiment

<ul class="summary-bullets"><li>Leerink previously estimated a $2.2 billion annual telehealth market if the FDA permitted all seven peptides reviewed in July.</li><li>Hims acquired a California peptide facility in February 2025 and has begun ingredient testing.</li><li>FDA advisers recommended six of seven peptides in July despite staff concerns about evidence and safety.</li></ul>Shares of Hims &amp; Hers Health (HIMS) jumped nearly 6% on Thursday, snapping a three-day losing streak as a Trump administration plan to ease restrictions on peptide compounding reached White House review.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is headed for its worst week in nearly two months, with shares down 5% for the week.&nbsp;<h2 class="st-heading-2">White House Reviews Peptide Access Plan</h2>A proposal sent for White House review would allow specialty pharmacies to temporarily compound certain unapproved peptides, including BPC-157, the Associated Press&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://apnews.com/article/peptides-kennedy-drugs-trump-bpc157-fb12641dfe791f443f7b7d1eb3bd4a0a">reported</a>, citing people familiar with the plan. BPC-157 is promoted for muscle building and injury recovery.An Office of Management and Budget posting on Thursday shows that the agency received the HHS/FDA proposal on Wednesday. Titled “Interim Access Policy for Compounding Using Certain Peptides,” the filing provides no details or implementation timetable.The proposal would apparently assure pharmacies they would not face enforcement action for producing covered peptides, an approach known as enforcement discretion. Permanently adding the substances to the FDA’s compounding list would require formal rulemaking. Health Secretary Robert F. Kennedy Jr. has advocated allowing U.S. pharmacies to sell peptides, saying Americans are already obtaining them through gray-market suppliers.<h2 class="st-heading-2">Hims Prepares For Potential $2.2B Market</h2>Leerink Partners previously estimated that allowing all seven peptides reviewed in July could create a $2.2 billion annual telehealth market, with Hims potentially capturing about 20%, or $440 million in annual sales. The brokerage called July’s advisory outcome a “positive catalyst” and identified BPC-157 as “likely one of the more commercially viable” peptides under review.Hims has been building its manufacturing and clinical capabilities ahead of a potential regulatory opening. The company acquired a California peptide manufacturing facility in early February 2025. On its recent earnings call, CEO Andrew Dudum said, “We’ve started validation and stability testing on APIs for those peptides developed in our Menlo Park facility.”Dudum also outlined work on clinical protocols and provider training, along with an offering that combines U.S.-manufactured products, clinical guidance, and ongoing blood testing.&nbsp;<h2 class="st-heading-2">FDA Advisers Back Access Despite Staff Concerns</h2>FDA advisers voted in July to recommend adding six of seven peptides to the 503A bulk substances list, despite agency scientists’ objections over limited evidence and unresolved safety concerns. The recommendations were nonbinding. For BPC-157, FDA briefing materials identified gaps in clinical evidence, chemical characterization, and impurity controls, as well as potential immune reactions.However, Hims medical chief Anant Vinjamoori still supported a supervised access pathway. “Millions of Americans are already accessing these treatments through the gray market,” he said in July. “Peptides are simply our newest frontier.”<h2 class="st-heading-2">How Do Retail Traders Feel About HIMS?</h2>On Stocktwits, retail sentiment for HIMS flipped to ‘bearish’ from ‘bullish’ levels a day ago amid a 178% jump in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_4aee1de1c2.png" alt="hims ss.png" width="637" height="348"><figcaption>HIMS sentiment and message volume as of October 15 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Arrie1982/message/666621813">said</a>, “$HIMS not just the option to sell peptides. You bring many new customers to the platform, possibly buying ED pills too! Normally you need to advertise to get them, now virtually for free. Adding more and more. 28 is a steal”<stembedurl>https://stocktwits.com/Arrie1982/message/666621813</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/ShyGuy82433/message/666649121">said</a>, “$HIMS this price action is comical. My prediction - we may get a pump once peptide compounding is officially signed and approved, then we’ll fade because HIMS won’t be ready to launch until EOY probably or early next year, then once we get a full quarter of earnings with peptides, we will really pump and this stock will be 100$+”<stembedurl>https://stocktwits.com/ShyGuy82433/message/666649121</stembedurl>HIMS stock has declined 10% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rklb-stock-cathie-wood-ark-dip-rocket-lab-mars-record-neutron-delay/cZx0ZX2RBrF">RKLB Stock’s Slide Hits Day 7: Cathie Wood’s ARK Buys The Dip As Rocket Lab Touts Mars Record Amid Neutron Delay&nbsp;</a>

 In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

HIMS Stock Snaps 3-Day Slump On Peptide Hopes: Trump Administration Reviews Plan That Could Unlock $2.2B Market

Hims & Hers Health Inc

Favorable

Unfavorable

Delayed

Hims & Hers ($HIMS) is bracing for a pivotal FDA advisory meeting on July 23-24 that will decide whether seven peptides get added to the compounding list. How do you think the FDA rules? Vote and explain your reasoning in the comments.

The FDA is deciding whether to add peptides to the compounding list, a ruling that could be huge for $HIMS. How do you think it goes?

Stocktwits

The FDA is deciding whether to add peptides to the compounding list, a ruling that could be huge for 

Stocktwits Polls

Investors are closely watching regulatory developments and FDA policy updates regarding peptide therapies as a key catalyst for future growth.

Traders are closely monitoring technical levels, specifically the 50-day moving average and a $32 price hurdle, for signs of a potential bullish breakout.

Debate persists between bears pointing to low volume and price weakness versus bulls looking for cover-induced volatility.

Current Price	$28.15
Prev Close	$28.07
Open	$28.49
Dividend Yield	0.00%
50-Day Moving Average	$29.25
Beta	2.37
Avg. Volume	9.57M
PE Ratio	-45.18

52-Week High	$51.36
52-Week Low	$13.74
Market Capitalization	$6.55B
EPS (Annual)	$0.5123
Price to Book	20.27
Revenue Per Employee	$961,358.31

Feed

News

Sentiment

Earnings

Fundamentals

Info

HIMS Fundamentals